Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer

Clinical Therapeutics

Volumn 33, Issue 9, 2011, Pages 1289-1305

  Squires, Hazel ^a   Tappenden, Paul ^a   Cooper, Katy ^a   Carroll, Christopher ^a   Logan, Richard ^b   Hind, Daniel ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Aspirin; Calcium; Celecoxib; Chemoprevention; Colorectal cancer; Health economics; Screening

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; CELECOXIB;

ADULT; ARTICLE; CANCER GROWTH; CANCER SCREENING; CHEMOPROPHYLAXIS; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; OCCULT BLOOD; POLYPECTOMY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; CALCIUM; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; OCCULT BLOOD; PYRAZOLES; QUALITY-ADJUSTED LIFE YEARS; SULFONAMIDES;

EID: 80053031301     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.07.009     Document Type: Article

References (49)

1. World Cancer Research Fund International, Accessed February 2009. http://www.wcrf.org/.
2. Large bowel (colorectal) cancer factsheet Cancer Research UK, Accessed February 2009. http://info.cancerresearchuk.org/cancerstats/types/bowel/?a=5441.
3. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
4. Atkin W.S., Saunders B.P. Surveillance guidelines after removal of colorectal adenomatous polyps. Gut 2002, 51(Suppl 5):V6-V9.
5. Carroll C., Cooper K., Papaioannou D., et al. Supplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysis. Clin Ther 2010, 32:789-803.
6. Cooper K., Squires H., Carroll C., et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2010, 14:1-206.
7. Tappenden P., Chilcott J., Eggington S., et al. Option appraisal of population-based colorectal cancer screening programmes in England. Gut 2007, 56:677-684.
8. Guide to the methodsoftechnologyapprasial National Institute for Health and Clinical Excellence, Accessed February 2009. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf.
9. Turnbull R.B., Kyle K., Watson F.R. Cancer of the colon: the influence of the no touch isolation technique on survival rates. Ann Surg 1967, 166:420-427.
10. Dukes C.E. The classification of cancer of the rectum. J Pathol Bacteriol 1932, 35:332.
11. Whyte S., Walsh C., Chilcott J. Bayesian calibration of a natural history model with application to a population model for colorectal cancer. Med Decis Making 2011, 31:625-641.
12. Cancer Registry population denominators 2009, United Kingdom Association of Cancer Registries, Experimental Statistics provided by Office for National Statistics Crown Copyright 2007.
13. Mortality statistics. Deaths registered in 2006 National Statistics Online, Accessed February 2009. http://www.statistics.gov.uk/downloads/theme_health/DR-2006/DR_06Mort_Stats.pdf.
14. Burch J.A., Soares-Weiser K., St.John D.J., et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen 2007, 14:132-137.
15. Weller D., Moss S., Butler P., et al. English Pilot of Bowel Cancer Screening: an evaluation of the second round. Final Report to the Department of Health. Institute of Cancer Research, 2006 Accessed February 2009. http://www.cancerscreening.nhs.uk/bowel/pilot-2nd-round-evaluation.pdf.
16. Van Rijn J.C., Reisma J.B., Stoker J. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006, 101:343-350.
17. Bressler B., Paszat L., Chen D., et al. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastoenterology 2007, 132:96-102.
18. Interim Life Tables 2005-07 Government Actuary's Department, Accessed February 2009. http://www.gad.gov.uk/Demography%20Data/Life%20Tables/Interim_life_tables.html.
19. Gatto N.M., Frucht H., Sundararajan V., et al. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst 2003, 95:230-236.
20. Farrell B., Godwin J., Richards S., Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991, 54:1044-1054.
21. Peto R., Gray R., Collins R., et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988, 296:313-316.
22. Flossmann E., Rothwell P.M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007, 369:1603-1613. British Doctors Aspirin Trial and the UK-TIA Aspirin Trial.
23. Imperiale T.F., Wagner D.R., Lin C.Y., et al. Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med 2002, 346:1781-1785.
24. Baron J.A., Sandler R.S., Bresalier R.S., et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131:1674-1682.
25. Arber N., Eagle C.J., Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885-895.
26. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355:873-884.
27. Dubé C., Rostom A., Lewin G., et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007, 146:365-375. [Summary for patients in Ann Intern Med. 2007;146:I35.].
28. Rostom A., Dubé C., Lewin G., et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007, 146:376-389. [Summary for patients in Ann Intern Med. 2007;146:I35.].
29. Bolland M.J., Barber P.A., Doughty R.N., et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008, 336:262-266.
30. Osteoarthritis: National Clinical Guideline for Care and Management in Adults 2008, National Collaborating Centre for Chronic Conditions, Appendix D, Royal College of Physicians, London, UK.
31. Ramsey S.D., Andersen M.R., Etzioni R., et al. Quality of life in survivors of colorectal cancer. Cancer 2000, 88:1294-1303.
32. Ness R.M., Holmes A.M., Klein R., Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 1999, 94:1650-1657.
33. Health Survey for England, 1996. Series HS no. 6 Department of Health, Accessed February 2009. http://www.dh.gov.uk/en/Publicationsandstatistics/PublishedSurvey/HealthSurveyForEngland/Healthsurveyresults/DH_4001554.
34. NHS Reference Costs 2006-07 Department of Health, Accessed February 2009. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082571.
35. Pilgrim H., Tappenden P., Chilcott J., et al. The costs and benefits of bowel cancer service developments using discrete event simulation. J Oper Res Soc 2009, 60:1305-1314.
36. Rothwell P.M., Wilson M., Elwin C.E., et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010, 376:1741-1750.
37. Rothwell P.M., Fowkes F.G., Belch J.F., et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
38. Bolland M.J., Avenell A., Baron J.A., et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010, 341:c3691.
39. Grau M.V., Baron J.A., Sandler R.S., et al. Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. J Natl Cancer Inst 2007, 99:129-136.
40. Atkin W.S., Edwards R., Kralj-Hans I., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010, 375:1624-1633.
41. Logan R.F., Grainge M.J., Shepherd V.C., et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008, 134:29-38. ukCAP Trial Group.
42. Cole B.F., Logan R.F., Halabi S., et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009, 101:256-266.
43. Benamouzig R., Deyra J., Martin A., et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003, 125:328-336.
44. Bonithon-Kopp C., Kronborg O., Giacosa A., et al. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 2000, 356:1300-1306.
45. Baron J., Beach M., Mandel J., et al. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 1999, 340:101-107.
46. British National Formulary 2008, Joint Formulary Committee, British Medical Association and Royal Pharmaceutical Society, London. 57. ed.
47. Curtis L. Unit Costs of Health and Social Care University of Kent: Personal Social Services Research Unit 2008.
48. NHS Reference Costs 2005 Department of Health, Accessed February 2009. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4133221.
49. NHS Reference Costs 2006-07 Department of Health, Accessed February 2009. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082571.